In short
The 2025 CANMAT guideline updates first-, second-, and third-line treatments for major depressive disorder (MDD), emphasizing measurement-based care, sequenced treatment, and the growing role of ketamine, esketamine, and augmentation strategies for treatment-resistant depression.
What this guide covers: What is major depressive disorder? · First-line treatment · Treatment-resistant depression · Special populations · Practical takeaway
What is major depressive disorder?
Major depressive disorder (MDD) is a common, recurrent mood disorder marked by persistently low mood and loss of interest or pleasure that impairs daily functioning. The 2025 CANMAT (Canadian Network for Mood and Anxiety Treatments) guideline is a widely used, evidence-graded reference for pharmacologic management.
First-line treatment
For most adults, first-line options remain SSRIs, SNRIs, and (where appropriate) bupropion or mirtazapine, chosen by side-effect profile, comorbidity, and patient preference. Measurement-based care—tracking symptoms with a validated scale at every visit—is recommended to guide dose changes and switches.
Treatment-resistant depression
After two failed adequate trials, MDD is considered treatment-resistant. The guideline elevates augmentation (e.g., with atypical antipsychotics) and, for appropriately selected patients, rapidly acting options such as ketamine or esketamine nasal spray, supported by stronger evidence than in prior editions.
Special populations
Dosing and drug choice are tailored for older adults, perinatal patients, and those with concurrent illness. The guideline stresses safety monitoring (e.g., for SSRIs in youth) and collaborative care.
Practical takeaway
If you are being treated for depression, expect systematic dose optimization and symptom tracking rather than a single fixed prescription. Ask your clinician about sequential, evidence-based options if the first treatment does not help.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.



